MedPath

IMCY-0141

Generic Name
IMCY-0141
Drug Type
Biotech

Overview

IMCY-0141 is a synthetic peptide based on MOG (Myelin Oligodendrocyte Glycoprotein), a dominant autoantigen, designed to stop the progression of multiple sclerosis (MS) and the destruction of the myelin sheath protecting the nerves.

Background

IMCY-0141 is a synthetic peptide based on MOG (Myelin Oligodendrocyte Glycoprotein), a dominant autoantigen, designed to stop the progression of multiple sclerosis (MS) and the destruction of the myelin sheath protecting the nerves.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Phase 1
Active, not recruiting
Posted: 2022/06/14
Sponsor:Imcyse SA

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath